Clinical Trial Detail

NCT ID NCT03092453
Title Dendritic Cell Vaccination in Patients With Advanced Melamona
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Pennsylvania
Indications

melanoma

Therapies

Cyclophosphamide + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.